P52.F NEWBURY PHARMACEUTICALS
- Market cap
- EUR 3.69M
- P/E
- -
- P/B
- 2.02x
- ROE
- -116.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Aug 2026.
Is P52.F undervalued?
Graham numberThe Graham number of NEWBURY PHARMACEUTICALS cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
NEWBURY PHARMACEUTICALS fundamental analysis
No fundamental analysis for NEWBURY PHARMACEUTICALS yet.
NEWBURY PHARMACEUTICALS stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About NEWBURY PHARMACEUTICALS
Newbury Pharmaceuticals AB (publ) operates as hybrid pharmaceutical company in Sweden and the Scandinavian market. It offers oncology, rare diseases, neurology, and other treatment products. Newbury Pharmaceuticals AB (publ) was incorporated in 2020 and is based in Lund, Sweden.
Full company profileNEWBURY PHARMACEUTICALS financial statements
NEWBURY PHARMACEUTICALS annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 5.52M | 10.3M | 36.8M | - | 42.7M |
| Gross Profit | 1.56M | 3.95M | 16.0M | - | 10.6M |
| Operating Income | -12.4M | -18.1M | -14.5M | -22.0M | -20.7M |
| EBITDA | -13.7M | -18.2M | -12.1M | -16.3M | -18.3M |
| Net Income | -14.7M | -19.4M | -15.4M | - | -22.9M |
| EPS | -0.75 | -1.00 | -0.64 | - | -0.75 |
| Balance Sheet | |||||
| Total Assets | 86.9M | 72.9M | 90.9M | - | 76.2M |
| Total Liabilities | 18.1M | 23.5M | 39.0M | - | 56.6M |
| Shareholders' Equity | 68.8M | 49.4M | 51.9M | - | 19.6M |
| Cash & Short-term Investments | 33.3M | 8.53M | 15.3M | - | 9.34M |
| Cash Flow | |||||
| Operating Cash Flow | -15.0M | -23.2M | -23.7M | - | -19.7M |
| Capital Expenditure | 24.4M | 862K | 2.91M | 2.21M | 0.00 |
| Free Cash Flow | -39.4M | -24.1M | -26.6M | -12.4M | -19.7M |
| Ratios | |||||
| ROE | -21.3% | -39.3% | -29.7% | - | -116.9% |
| ROA | -16.9% | -26.6% | -17.0% | - | -30.1% |
| Net Profit Margin | -265.9% | -189.3% | -41.8% | - | -53.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
NEWBURY PHARMACEUTICALS dividends
NEWBURY PHARMACEUTICALS has not paid dividends in the last 5 fiscal years.
Who owns NEWBURY PHARMACEUTICALS
- Insiders 74.11%
- Institutions 4.85%
- Public & others 21.04%
- Shares outstanding 30.4M
- Free float 6.73M
NEWBURY PHARMACEUTICALS company profile
- Company name
- NEWBURY PHARMACEUTICALS
- Ticker
- P52.F
- ISIN
- SE0015244884
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 7
- Fiscal year end
- August
- Address
- Medicon Village, Lund, Sweden, 223 81
- Phone
- 46 46 12 11 20
- Website
- newburypharma.com
About NEWBURY PHARMACEUTICALS
Newbury Pharmaceuticals AB (publ) operates as hybrid pharmaceutical company in Sweden and the Scandinavian market. It offers oncology, rare diseases, neurology, and other treatment products. Newbury Pharmaceuticals AB (publ) was incorporated in 2020 and is based in Lund, Sweden.
NEWBURY PHARMACEUTICALS management
3- Mr. Karl Alexius Tiger KarlssonFounder, CEO & Director · born 1974
- Mr. Christoffer TellChief Financial Officer · born 1987
- Mr. Fredrik HellqvistGeneral Manager for Nordics · born 1973